This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: June 9, 2011
Last updated: April 3, 2012
Last verified: April 2012
GSK1120212 is a reversible and highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity currently being developed for the treatment of malignant melanoma. This is a Phase I, open-label, non-randomized, single-dose study designed to characterize the absorption, distribution, metabolism, and elimination (ADME) of a single oral dose of MEK inhibitor [14C]GSK1120212 as a solution in male subjects with solid tumor malignancies. A sufficient number of subjects will be enrolled to complete approximately four evaluable subjects. Following completion of the study, subjects may elect to continue dosing with GSK1120212 in the rollover study, MEK114375.

Condition Intervention Phase
Solid Tumours Cancer Drug: GSK1120212 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Mass Balance Study to Investigate the Absorption, Distribution, Metabolism and Elimination of a Single Oral Dose of MEK Inhibitor [14C]GSK1120212 in Male Subjects With Solid Tumors

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Total excretion of radioactivity [ Time Frame: 11 days ]
    • Total and relative excretion of radioactivity in urine and feces following a single, 2 mg oral solution dose of [14C]GSK1120212

Secondary Outcome Measures:
  • Total radioactivity concentration in blood and plasma [ Time Frame: 11 days ]
    AUC(0- t), AUC(0-∞), Cmax, tmax and t1/2

  • Characterize and quantify metabolites in urine plasma and feces [ Time Frame: 11 days ]
    Characterize and quantify metabolites of GSK1120212 in plasma, urine and feces (studied separately under a DMPK protocol).

  • Assess covalent binding of drug related material to plasma proteins [ Time Frame: 11 days ]
    Assess percentage of drug-related material that covalently bonds to plasma proteins (studied separately under a DMPK protocol)

  • Blood:plasma ratio [ Time Frame: 11 days ]
    Blood:plasma ratio of total drug-related material (radioactivity)

  • Pharmacokentic concentrations in plasma [ Time Frame: 11 days ]
    Plasma GSK1120212 concentrations AUC(0-t), AUC(0-∞), Cmax, tmax, and t1/2

  • AEs [ Time Frame: From dosing on Day 1 to Follow-up ]
    Number of adverse events (AEs)

  • Vital signs [ Time Frame: Screening, Day -1, Day 1, Day 5, and Follow-up ]
    Changes from baseline

  • ECGs [ Time Frame: Screening, Day 1 pre-dose, 24 hours, Day 11 and Follow-up ]
    Changes from baseline

  • Clinical Laboratory assessments [ Time Frame: Screening, Day -1, and Day 11 ]
    Changes from baslines

Enrollment: 2
Study Start Date: February 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single-Dose, 2 mg [14C]GSK1120212
A single 2 mg (2 mg/10mL) oral dose of [14C]GSK1120212 containing approximately 79 μCi of radioactivity will be delivered as a solution.
Drug: GSK1120212
The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male 18 years old or older.
  2. Written informed consent provided
  3. Body weight greater than or equal to 45 kg and a BMI greater than or equal to 19 kg/m2 and less than or equal to 35 kg/m2 (inclusive).
  4. Able to swallow and retain oral medication.
  5. Histologically or cytologically confirmed diagnosis of a solid tumor.
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  7. Agree to use one of the contraception methods listed in the protocol from the time of the first dose of study medication until sixteen weeks after the last dose of study medication.
  8. A history of regular bowel movements (approximately once per day).
  9. Adequate baseline organ function as listed in the protocol.

Exclusion Criteria:

  1. Currently receiving cancer therapy as specified in the protocol.
  2. Serious and/or unstable pre-existing medical psychiatric disorder, or other conditions.
  3. Any major surgery within the last four weeks.
  4. Unresolved toxicity equal to or greater than Grade 2 from previous anti-cancer therapy except alopecia.
  5. An occupation within the past 12 months which requires monitoring for radiation exposure, nuclear medicine procedures or excessive x-rays.
  6. Radiation exposure from the previous three year period over 10 mSv if exposed to ionizing radiation above background as a result of work with radiation as category A (classified) workers or as a result of research studies.
  7. History of interstitial lung disease or pneumonitis.
  8. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to dimethyl sulfoxide (DMSO).
  9. Current use of a prohibited medications described in the protocol.

    • Use of anticoagulants such as warfarin is permitted.

  10. History RVO or CSR.

    • Predisposing factors to RVO or CSR.
    • Visible retinal pathology that is considered a risk factor for RVO or CSR such as:

      - Evidence of new optic disc cupping

      - Intraocular pressure greater than 21 mm Hg as measured by tonography. 11.1. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. (Previously treated and have had stable CNS disease for greater than 3 months, asymptomatic and off corticosteroids, or on stable dose of corticosteroids for at least 1 month prior to study Day 1 are permitted).

11.2. Receiving enzyme inducing anti-epileptic drugs (EIAEDs). 12. History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within the past 6 months. 13. QTcB greater than or equal to 480 msec. 14. History or evidence of current clinically significant uncontrolled arrhythmias.

15. History or evidence of current greater than or equal to Class II congestive heart failure.

16. Active gastrointestinal disease or other condition (e.g., gastrectomy, bariatric surgery, small bowel or large bowel resection, or cholecystectomy).

17. A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus.

18. Alcohol or drug abuse within six months prior to screening. 19. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs or excipients.

20. Participated in a clinical trial and has received an investigational product within 30 days or five half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) before the 1st dose.

21. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.

22. Mentally or legally incapacitated.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01387204

United States, Washington
GSK Investigational Site
Tacoma, Washington, United States, 98418
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

LoRusso PM, Krishnamurthi S, Rinehart JR, et al. A Phase 1-2 clinical study of the second-generation MEK inhibitor, PD 0325901 in patients with advanced cancer. J Clin Oncol. 2005; 23:3011.
GlaxoSmithKline Document Number RD2009/01379/00. Dosimetry Review for oral [14C]GSK1120212. Report Date 19-Nov-2009.
LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Croghan GA, Chapman PB, Selaru P, Kim S, Ricart AD, Wilner KD. Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer. Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007; 6:3649s [abstr B113].
GlaxoSmithKline Document Number HM2009/00151/01 GSK1120212 Investigator's Brochure Report Date 4 June 2010.
NCI. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. DHHS,NCI, NIH, Bethesda, MD; 2009.
GlaxoSmithKline Document Number RM2007/00642/03. MEK111054: An open-label, multiple-dose, dose escalation study to investigate the safety, harmacokinetics, and pharmacodynamics of the MEK inhibitor GSK1120212 in subjects with solid tumors or lymphoma. 2009.
Tzekova, V, Cebotaru C, Ciuleanu TE, et al. Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2008; 26:431s.

Responsible Party: GlaxoSmithKline Identifier: NCT01387204     History of Changes
Other Study ID Numbers: 113708
Study First Received: June 9, 2011
Last Updated: April 3, 2012

Keywords provided by GlaxoSmithKline:
MEK inhibitor
Phase 1
radiolabeled ADME

Additional relevant MeSH terms:
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017